BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25379815)

  • 21. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
    Olofsson T; Petersson IF; Eriksson JK; Englund M; Nilsson JA; Geborek P; Jacobsson LTH; Askling J; Neovius M;
    Ann Rheum Dis; 2017 Jul; 76(7):1245-1252. PubMed ID: 28073801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Karlsson JA; Englund M; Petersson IF; Saxne T; Geborek P
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1362-9. PubMed ID: 20506310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
    Gomez-Reino JJ; Carmona L;
    Arthritis Res Ther; 2006; 8(1):R29. PubMed ID: 16507128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
    Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS; Makovey J; Lassere M; Buchbinder R; March LM
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment outcome of spondyloarthropathy with infliximab].
    Głowska A; Wiland P; Szechiński J
    Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.
    Neovius M; Sundström A; Simard J; Wettermark B; Cars T; Feltelius N; Askling J; Klareskog L;
    Scand J Rheumatol; 2011 Jan; 40(1):8-15. PubMed ID: 20955087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
    J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
    Kristensen LE; Petersson IF; Geborek P; Jöud A; Saxne T; Jacobsson LT; Englund M
    Rheumatology (Oxford); 2012 Feb; 51(2):243-9. PubMed ID: 21565900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.